Clinical trial
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
NCT00085813 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00085813 |
|---|---|
| Title | Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer |
| Official title | A Phase II, Open-Label Study of Ispinesib in Subjects With Locally Advanced or Metastatic Platinum-Refractory or Platinum-Relapsed Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Ispinesib |
| Enrollment | 70 |
| Start date | Dec 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jun 17, 2004 |
| Last update posted | Oct 4, 2010 |
| Countries | Belgium, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: